LDS/Medical Tests/Runt Related Transcription Factor 1 (RUNX1) Gene Mutation Analysis

Runt Related Transcription Factor 1 (RUNX1) Gene Mutation Analysis

The RUNX1 gene, also known as AML1, is located on the long (q) arm of chromosome 21 at position 22.12 and encodes the runt-related transcription factor 1 (core-binding factor subunit alpha-2). RUNX1 is a transcription factor that regulates the differentiation of hematopoietic stem cells into mature blood cells. In addition, it plays a major role in the development of neurons that transmit pain sensations. Germline mutations in RUNX1 are associated with familial platelet disorder with related myeloid malignancy. Somatic mutations of RUNX1 are frequently observed in myelodysplastic syndrome and leukemias of both myeloid and lymphoid lineages. Most mutations appear to have an inactivating effect on RUNX1 function, either by affecting the DNA-binding RUNT domain or by disrupting the C-terminal protein interaction domain. Mutations outside these regions appear to affect RUNX1 interactions with epigenetic regulators like the mixed-lineage leukemia (MLL) gene, thereby affecting histone methylation. Both clonal and subclonal RUNX1 mutations appear to confer a poor prognosis in myelodysplastic syndromes (MDS) patients, irrespective of other prognostic factors.

The t(8;21) translocation forming a pathological RUNX1-RUNX1T1 fusion leads to the disruption of the normal function of the core-binding factor, namely, its role in hematopoietic differentiation and maturation. RUNX1-RUNX1T1 directly regulates transcription and blocks differentiation thereby promoting leukemia progression. Although t(8;21) fusion protein is important for leukemia development, a mutation in one or more additional genes is typically needed for the myeloid blasts to develop into leukemic cells. In addition to t(8;21), more than 50 chromosome translocations affect RUNX1. The more common, recurrent translocations include t(12;21) in pediatric ALL and t(3;21) in therapy-related AML and MDS, which generate ETV6-RUNX1 (also known as TEL-AML1) and RUNX1-MECOM (including MDS1 and EVI1) fusions, respectively. Alterations of the RUNX1 transcription factor can influence the outcome of patients with AML. In the case of missense or frameshift mutations, RUNX1 has a negative effect and affected patients have a considerably shorter survival compared to those without these mutations. In contrast, the RUNX1/RUNX1T1 fusion in core binding factor AML is associated with a more favorable outcome in comparison to patients without fusions.

  • For the differential diagnosis of familial platelet disorder with predisposition to acute myeloid leukemia (FPD/AML) and sporadic myelodysplastic syndrome
  • To determine prognosis of patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myelomonocytic leukemia
  • Monitor patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)
  • To monitor for minimal residual disease and assess the risk of disease relapse
Mutation in RUNX1 gene or chromosomal translocation of RUNX1 gene forming RUNX1/RUNX1T1 fusion protein. Mutation may be frameshift insertions or deletions or nonsense or missense substitutions.

Negative for mutation analyze or chromosomal translocation in RUNX1 gene

RUNX1 mutations are detected and characterized by PCR amplification and direct sequencing of the coding and junctional regions of RUNX1 exons 1 – 8, Translocation of RUNX1 is detected by Fluorescence in situ Hybridization (FISH).

Peripheral blood (EDTA), Bone marrow aspirate.

Stability

  • Ambient: 72 hours
  • Refrigerated: 7 days
  • Frozen: Unacceptable
Acute Myeloid leukemia (AML) via the CEBPA gene, Bleeding Disorders Panel, Cancer Panel, Thrombocytopenia Panel, Bone Marrow Failure Syndrome Panel, Comprehensive Hereditary Cancer Panel, Platelet Function Disorder Panel, Comprehensive Hematology Panel, Comprehensive Hematology and Hereditary Cancer Panel, Thrombocytopenia Panel, Hereditary Leukemia Panel, Hereditary Pediatric Cancer Panel, Bleeding Disorder/Coagulopathy Panel.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Blood Adv. 2020 Jan 14;4: 229-238. [PMID: 31935293]
  • Int J Mol Sci 2019; 20: 1717. [PMID: 30959925]
  • Hemasphere. 2019;3: e178. [PMID: 31723813]
  • Front Cell Dev Biol. 2017; 5: 111. [PMID: 29326930]
  • Int J Hematol Oncol Stem Cell Res 2017; 11: 328-339. [PMID: 29340131]
  • Leukemia. 2014;28: 1449-58. [PMID: 24402164]
  • Genetics Home Reference. Available at: https://ghr.nlm.nih.gov/gene/RUNX1#
  • Christopher J. Gibson, Benjamin L. Ebert, and David P. Steensma, Haematology (seventh edition) In:Chapter 60, myelodysplastic syndrome. 2018: 944-969.e13